Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Infect Dis Clin North Am. 2019 Jun;33(2):593–609. doi: 10.1016/j.idc.2019.02.007

Table 2:

Summary findings on safety and efficacy of inactivated zoster vaccines in autologous SCT recipients

Study Study population Outcomes assessed Dosing schedule (days in relation to SCT) Findings
de la Serna et al.73
Recombinant subunit (RZV)
Phase 3 observer-blind, placebo controlled, randomized 1:1
Modified cohort:
RZV n=870
placebo n=851
median follow up=21 months		 Adult autologous
SCT recipients		 Clinical Efficacy (Primary)
Safety (Primary)		 2 doses
1: +50 to +70
2: +80 to +130 (or 30 to 60 days after dose 1)		 Incident disease (per person, vaccine vs placebo)

  • HZ: 49 vs 135 (68.2% efficacy)

  • PHN: 1 vs 9 (89.3% efficacy)
Winston et al.74
Heat inactivated VZV vaccine (investigational)
Phase 3 double-blind, placebo-controlled, randomized 5:1:5
Vaccine lot n=560
Hi antigen lot n=164
Placebo n=564
Mean follow up=2.4 years		 Adult autologous
SCT recipients
2010–2013
135 centers		 Clinical Efficacy (Primary)
Safety (Primary-hi lot group)
Immunogenicity (Secondary)		 4 doses
1: −5 to −60
2:+30
3:+60
4:+90		 Incident disease (per 1000 person-years, vaccine lot vs placebo):

  • HZ: 32.9/vs 91.9 (63.9% efficacy)

  • PHN: 2.3 vs 14.6 (83.7% efficacy)


VZV-specific responses higher in vaccine group; T cell responses sustained at 3 years; B cell responses plateau after 1 year

HZ, herpes zoster; PHN, post herpetic neuralgia